| Ruling Favors Anthrax-Vaccine Maker Biotechnology company, PharmAthene, won a ruling allowing it to keep a government contract worth about $78 million for developing a new anthrax vaccine. online.wsj.com |
Taking Jargon Out of Doctor Visits Officials are pushing for medical providers to simplify the language they use to communicate with the public, in a move to improve patient outcomes and reduce costs. online.wsj.com |
BioClinica to Demonstrate Global Technology-Enhanced Trial Service Capabilities at Leading Industry Events (Business Wire) NEWTOWN, Pa.----BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, will attend and speak at several key industry conferences throughout the third and fourth quarters of 2010. us.rd.yahoo.com |
Crucell Deal Will Expand J&J’s Position in Growing Vaccine Market: Biotech's Latest M&A Activity The Burrill Report submits: By Marie DaghlianJohnson & Johnson (JNJ) and Crucell (CRXL) are in advanced negotiations for the pharmaceutical giant to make a public offer for all outstanding shares of the Dutch vaccine maker. The potential deal is valued at $2.3 billion (€1.75 billion), which represents a purchase price of €25.75 per share, a 58 percent premium over Crucell’s closing price on September 16. Complete Story » seekingalpha.com |
LTX-Credence CEO Discusses F1Q2011 Results - Earnings Call Transcript LTX-Credence CorporationF1Q2011 (Qtr 10/31/10) Earnings Conference CallNovember 23, 2010 10:00 AM ETComplete Story » seekingalpha.com |